Read More About Medicines in Development for Cancer

Medicines in Development for Cancer

America’s biopharma research companies are testing 981 medicines and vaccines to fight the many types of cancer affecting millions of patients worldwide. All of the medicines are either in clinical trials or awaiting review by the Food and Drug Administration (FDA).

“Despite amazing strides in the ongoing battle against cancer, the many forms of this disease remain a major public health challenge for patients, their families, healthcare providers and economies in the United States and throughout the world,” said PhRMA President and CEO John J. Castellani. “The ceaseless efforts of biopharmaceutical researchers in America have brought new and improved treatment options to patients, creating hope that didn’t exist before. This report represents the next chapter of hope; it’s a story of amazing science, individual perseverance and a sector-wide commitment to patients.”

Over the last few decades, remarkable progress in biopharma R&D has led to steady improvements in cancer survivorship rates in the U.S. According to the CDC, there were 11.7 million cancer survivors in the U.S. in 2007, up from 9.8 million in 2001 and 3 million in 1971. The increase in survivors is attributed in large measure to earlier diagnosis and detection, and better treatments and follow-up care.

Related Information


More On PhRMA — powered by PhRMApedia